{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:58:28Z","timestamp":1763755108542,"version":"3.45.0"},"reference-count":98,"publisher":"Oncology Nursing Society (ONS)","issue":"0","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2007,2,1]]},"DOI":"10.1188\/07.cjon.s1.23-36","type":"journal-article","created":{"date-parts":[[2007,10,29]],"date-time":"2007-10-29T08:09:22Z","timestamp":1193645362000},"page":"23-36","source":"Crossref","is-referenced-by-count":0,"title":["Emerging Therapeutic Options for B-Cell Disorders:Idiopathic Thrombocytopenic Purpura and Chronic Lymphocytic Leukemia"],"prefix":"10.1188","volume":"11","author":[{"given":"Amy","family":"Goodrich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2007,10,25]]},"reference":[{"key":"E00001","doi-asserted-by":"crossref","unstructured":"Abbott, B.L. (2006). Chronic lymphocytic leukemia: Recent advances in diagnosis and treatment. <i>Oncologist, 11<\/i>, 21-30.","DOI":"10.1634\/theoncologist.11-1-21"},{"key":"E00002","unstructured":"American Cancer Society. (2006a). <i>Cancer facts and figures 2006.<\/i> Atlanta, GA: Author."},{"key":"E00003","unstructured":"American Cancer Society. (2006b). <i>Leukemia: Chronic lymphocytic.<\/i> Retrieved August 11, 2006, from <a target=\"_blank\" href='http:\/\/www.cancer.org\/6893.00\/6893.00pdf'>http:\/\/www.cancer.org\/6893.00\/6893.00pdf<\/a>"},{"key":"E00004","unstructured":"Arnold, D.M., Dentali, F., Meyer, R.M., Crowther, M.A., Sigouin, C., & Kelton, J.G. (2005). Rituximab for the treatment of adults with ITP: A systematic review [Abstract 1241]. <i>Blood, 106<\/i>, 1241."},{"key":"E00005","doi-asserted-by":"crossref","unstructured":"Baldwin, P.D. (2003). Thrombocytopenia. <i>Clinical Journal of Oncology Nursing, 7<\/i>, 349-352.","DOI":"10.1188\/03.CJON.349-352"},{"key":"E00006","unstructured":"Berlex. (2003). Fludara\u00ae (fludarabine sulfate) [Prescribing information]. Montville, NJ: Author."},{"key":"E00007","unstructured":"Berlex. (2005). Campath\u00ae (alemtuzumab) [Prescribing information]. Montville, NJ: Author."},{"key":"E00008","doi-asserted-by":"crossref","unstructured":"Binet, J.L., Auquier, A., Dighiero, G., Chastang, C., Piquet, H., Goasquen, J., et al. (1981). A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate analysis. <i>Cancer, 48<\/i>, 198-206.","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V"},{"key":"E00009","doi-asserted-by":"crossref","unstructured":"Braendstrup, P., Bjerrum, O.W., Nielsen, O.J., Jensen, B.A., Clausen, N.T., Hansen, P.B., et al. (2005). Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. <i>American Journal of Hematology, 78<\/i>, 275-280.","DOI":"10.1002\/ajh.20276"},{"key":"E00010","unstructured":"British Society for Haematology. (2003). Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. <i>British Journal of Haematology, 120<\/i>, 574-596."},{"key":"E00011","unstructured":"Byrd, J.C., Flinn, I.W., Khan, K.D., Kipps, T.J., Aukerman, L., Fox, J., et al. (2006). Pharmacokinetics and pharmacodynamics from a first-in-human phase 1 dose escalation study with antagonist anti-CD40 antibody, HCD122 (formerly CHIR-1212), in patients with relapsed and refractory chronic lymphocytic leukemia [Abstract 2837]. <i>Blood, 108<\/i>(Pt. 1), 803a."},{"key":"E00012","doi-asserted-by":"crossref","unstructured":"Byrd, J.C., Murphy, T., Howard, R.S., Lucas, M.S., Goodrich, A., Park, K., et al. (2001). Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. <i>Journal of Clinical Oncology, 19<\/i>, 2153-2164.","DOI":"10.1200\/JCO.2001.19.8.2153"},{"key":"E00013","doi-asserted-by":"crossref","unstructured":"Byrd, J.C., Peterson, B.L., Morrison, V.A., Park, K., Jacobson, R., Hoke, E., et al. (2003). Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from the Cancer and Leukemia Group B 9712 (CALGB 9712). <i>Blood, 101<\/i>, 6-14.","DOI":"10.1182\/blood-2002-04-1258"},{"key":"E00014","doi-asserted-by":"crossref","unstructured":"Byrd, J.C., Stilgenbauer, S., & Flinn, I.W. (2004). Chronic lymphocytic leukemia. <i>Hematology, 2004<\/i>, 163-183.","DOI":"10.1182\/asheducation-2004.1.163"},{"key":"E00015","unstructured":"Case, D.C., Jr., Hedlund, J.A., Ebrahim, K.S., & Boyd, M.A. (2005). Rituximab produces long-term responses in immune thrombocytopenic purpura (ITP) [Abstract 3977]. <i>Blood, 106<\/i>(Pt. 2), 74b."},{"key":"E00016","doi-asserted-by":"crossref","unstructured":"Catovsky, D. (2004). Definition and diagnosis of sporadic and familial chronic lymphocytic leukemia. <i>Hematology\/Oncology Clinics of North America, 18<\/i>, 783-794.","DOI":"10.1016\/j.hoc.2004.04.009"},{"key":"E00017","doi-asserted-by":"crossref","unstructured":"Chanan-Khan, A.A., Miller, K.C., Musial, L., Padmanabhan, S., Lawrence, D., Bernstein, Z.P., et al. (2006). Clinical efficacy of lenalidomide {Revlimid\u00ae} in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): Updated results of a phase II clinical trial [Abstract 306]. <i>Blood, 108<\/i>(Pt. 1), 95a.","DOI":"10.1182\/blood.V108.11.306.306"},{"key":"E00018","doi-asserted-by":"crossref","unstructured":"Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S., et al. (1996). National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. <i>Blood, 87<\/i>, 4990-4997.","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"E00019","unstructured":"Cho, Y.G., Lee, J.H., Kim, D.S., Lee, H.S., & Choi, S.I. (2006). Clinical usefulness of the simple technique to diagnose thrombocytopenia using immature platelet fraction (IPF) [Abstract 3950]. <i>Blood, 108<\/i>(Pt. 2), 65b."},{"key":"E00020","doi-asserted-by":"crossref","unstructured":"Cines, D.B., & Bussel, J.B. (2005). How I treat idiopathic thrombocytopenic purpura (ITP). <i>Blood, 106<\/i>, 2244-2251.","DOI":"10.1182\/blood-2004-12-4598"},{"key":"E00021","doi-asserted-by":"crossref","unstructured":"Cooper, N., Stasi, R., Cunningham-Rundles, S., Feuerstein, M.A., Leonard, J.P., Amadori, S., et al. (2004). The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. <i>British Journal of Haematology, 125<\/i>, 232-239.","DOI":"10.1111\/j.1365-2141.2004.04889.x"},{"key":"E00022","doi-asserted-by":"crossref","unstructured":"Crespo, M., Bosch, F., Villamor, N., Bellosillo, B., Colomer, D., Rozman, M., et al. (2003). ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. <i>New England Journal of Medicine, 348<\/i>, 1764-1775.","DOI":"10.1056\/NEJMoa023143"},{"key":"E00023","doi-asserted-by":"crossref","unstructured":"Crow, A.R., Song, S., Siragam, V., & Lazarus, A.H. (2006). Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia. <i>Pediatric Blood and Cancer, 47<\/i>(5, Suppl.), 710-713.","DOI":"10.1002\/pbc.20980"},{"key":"E00024","doi-asserted-by":"crossref","unstructured":"Damle, R., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S.L., et al. (1999). Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. <i>Blood, 94<\/i>, 1840-1847.","DOI":"10.1182\/blood.V94.6.1840"},{"key":"E00025","unstructured":"Delmer, A., Lepretre, S., Cazin, B., Feugier, P., Tournilhac, O., Leporrier, M., et al. (2006). Consolidation therapy with subcutaneous alemtuzumab following induction treatment with oral FC (fludarabine and cyclophosphamide) in previously untreated patients aged 65-70 years with advanced stage chronic lymphocytic leukemia (CLL): A phase II trial of the FCGCLL\/MW [Abstract 2831]. <i>Blood, 108<\/i>(Pt. 1), 801a."},{"key":"E00026","doi-asserted-by":"crossref","unstructured":"Dighiero, G., Maloum, K., Desablens, B., Cazin, B., Navarro, M., Leblay, R., et al. (1998). Chlorambucil in indolent chronic lymphocytic leukemia. <i>New England Journal of Medicine, 338<\/i>, 1506-1514.","DOI":"10.1056\/NEJM199805213382104"},{"key":"E00027","doi-asserted-by":"crossref","unstructured":"Dohner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., et al. (1995). p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. <i>Blood, 85<\/i>, 1580-1589.","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580"},{"key":"E00028","unstructured":"Eichhorst, B.F., Busch, R., Hopfinger, G., Pasold, R., Hensel, M., Steinbrecher, C., et al. (2006). Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. <i>Blood, 107<\/i>, 885-891."},{"key":"E00029","doi-asserted-by":"crossref","unstructured":"Ellis, D.W., Eaton, M., Fox, R.M., Juneja, S., Leong, A.S., Miliauskas, J., et al. (2005). Diagnostic pathology of lymphoproliferative disorders. <i>Pathology, 37<\/i>, 434-456.","DOI":"10.1080\/00313020500370309"},{"key":"E00030","doi-asserted-by":"crossref","unstructured":"Elter, T., Borchmann, P., Schulz, H., Reiser, M., Trelle, S., Schnell, R., et al. (2005). Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: Results of a phase II trial. <i>Journal of Clinical Oncology, 23<\/i>, 7024-7031.","DOI":"10.1200\/JCO.2005.01.9950"},{"key":"E00031","doi-asserted-by":"crossref","unstructured":"Fabris, F., Allemand, E., Scandellari, R., Vettore, S., Randi, M.L., & Luzzatto, G. (2005). Helicobacter pylori infection and clinical response to eradication therapy in patients with immune thrombocytopenic purpura (ITP) [Abstract 3996]. <i>Blood, 106<\/i>(Pt. 2), 3996.","DOI":"10.1182\/blood.V106.11.3996.3996"},{"key":"E00032","doi-asserted-by":"crossref","unstructured":"Faderl, S., Ferrajoli, A., Wierda, W., O'Brien, S., Ravandi-Kashani, F., Fayad, L., et al. (2006). The combination of alemtuzumab [continuous intravenous infusion (civ) followed by subcutaneous injection (sc)] plus rituximab has activity in patients (pts) with relapsed chronic lymphocytic leukemia (CLL) [Abstract 2827]. <i>Blood, 108<\/i>(Pt. 1), 800a.","DOI":"10.1182\/blood.V108.11.2827.2827"},{"key":"E00033","doi-asserted-by":"crossref","unstructured":"Faderl, S., Wierda, W.S., O'Brien, S., Ferrajoli, A., Ravandi-Kashani, F., Detry, M., et al. (2006). Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) as frontline therapy for CLL: Results of a phase 2 study [Abstract 2836]. <i>Blood, 108<\/i>(Pt. 1), 803a.","DOI":"10.1182\/blood.V108.11.2836.2836"},{"key":"E00034","doi-asserted-by":"crossref","unstructured":"Ferrajoli, A., & Keating, M.J. (2004). Current guidelines in defining therapeutic strategies. <i>Hematology\/Oncology Clinics of North America, 18<\/i>, 881-893.","DOI":"10.1016\/j.hoc.2004.04.006"},{"key":"E00035","unstructured":"Ferrajoli, A., O'Brien, S.M., Faderl, S.H., Wierda, W.G., Davis, D., Lee, B.N., et al. (2006). Lenalidomide induces complete and partial responses in patients with relapsed and treatment-refractory chronic lymphocytic leukemia (CLL) [Abstract 305]. <i>Blood, 108<\/i>(Pt. 1), 94a."},{"key":"E00036","unstructured":"Ferrajoli, A., O'Brien, S.M., Faderl, S.H., Wierda, W.G., Ravandi-Kashani, F., O'Neal, B., et al. (2005). Rituximab plus GM-CSF for patients with chronic lymphocytic leukemia [Abstract 721]. <i>Blood, 106<\/i>(Pt. 1), 214a."},{"key":"E00037","unstructured":"Garcia-Chavez, J., Vela-Ojeda, J., Gonzalez-Acosta, J.C., & Ovilla-Martinez, R. (2005). Treatment of refractory chronic immune thrombocytopaenic purpura (ITP) with rituximab: Report of a cases series [Abstract 4007]. <i>Blood, 106<\/i>(Pt. 2), 81b."},{"key":"E00038","unstructured":"Genentech BioOncology. (2005). Rituxan\u00ae (rituximab) [Product information]. South San Francisco, CA: Author."},{"key":"E00039","unstructured":"George, J.N., Bussel, J.B., McMillan, R., Guo, M., Okano, G.J., & Nichol, J.L. (2006). Analysis of health-related quality of life in patients receiving AMG 531 using the disease-specific immune thrombocytopenic purpura patient assessment questionnaire [Abstract 3292]. <i>Blood, 108<\/i>(Pt. 1), 939a."},{"key":"E00040","doi-asserted-by":"crossref","unstructured":"George, J.N., Woolf, S.H., Raskob, G.E., Wasser, J.S., Aledort, L.M., Ballem, P.J., et al. (1996). Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. <i>Blood, 88<\/i>, 3-40.","DOI":"10.1182\/blood.V88.1.3.3"},{"key":"E00041","doi-asserted-by":"crossref","unstructured":"Giagounidis, A.A., Anhuf, J., Schneider, P., Germing, U., Sohngen, D., Quabeck, K., et al. (2002). Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: A pilot study. <i>European Journal of Haematology, 69<\/i>, 95-100.","DOI":"10.1034\/j.1600-0609.2002.02686.x"},{"key":"E00042","doi-asserted-by":"crossref","unstructured":"Gowda, A.C., Zhao, X.B., Cheney, C., Mehter, N., Lozanski, G., Lin, T.S., et al. (2005). Humanized anti CD-40 antibody SGN-40 effectively induces cytotoxicity against chronic lymphocytic leukemia (CLL) cells through antibody mediated cytotoxicity and demonstrates modest biologic evidence of CD40 activation [Abstract 2966]. <i>Blood, 106<\/i>(Pt. 1), 832a.","DOI":"10.1182\/blood.V106.11.2966.2966"},{"key":"E00043","doi-asserted-by":"crossref","unstructured":"Hainsworth, J.D., Litchy, S., Barton, J.H., Houston, G.A., Hermann, R.C., Bradof, J., et al. (2003). Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. <i>Journal of Clinical Oncology, 21<\/i>, 1746-1751.","DOI":"10.1200\/JCO.2003.09.027"},{"key":"E00044","doi-asserted-by":"crossref","unstructured":"Hamblin, T.J., Orchard, J.A., Ibbotson, R.E., Davis, Z., Thomas, P.W., Stevenson, F.K., et al. (2002). CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. <i>Blood, 99<\/i>, 1023-1029.","DOI":"10.1182\/blood.V99.3.1023"},{"key":"E00045","unstructured":"Hillmen, P., Skotnicki, A., Robak, T., Jaksic, B., Dmoszynska, A., Sirard, C., et al. (2006). Preliminary phase 3 efficacy and safety of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (B-CLL) [Abstract 6511]. <i>Journal of Clinical Oncology, 24<\/i>(18, Suppl.), 6511."},{"key":"E00046","unstructured":"Hoffman, R., Benz, E.J., Shattil, S.J., Furie, B., Cohen, H.J., Silberstein, L., et al. (Eds.). (2005). <i>Hematology: Basic principles and practices<\/i> (4th ed.). Orlando, FL: Saunders."},{"key":"E00047","doi-asserted-by":"crossref","unstructured":"Howard, J., Hoffbrand, A.V., Prentice, H.G., & Mehta, A. (2002). Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anoemia and auto-immune thrombocytopenia purpura. <i>British Journal of Haematology, 117<\/i>, 712-715.","DOI":"10.1046\/j.1365-2141.2002.03430.x"},{"key":"E00048","doi-asserted-by":"crossref","unstructured":"Huhn, D., von Schilling, C., Wilhelm, M., Ho, A.D., Hallek, M., Kuse, R., et al. (2001). Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. <i>Blood, 98<\/i>, 1326-1331.","DOI":"10.1182\/blood.V98.5.1326"},{"key":"E00049","unstructured":"Johansson, E., Engervall, P., Landgren, O., Grimfors, G., Widell, S., Rezai, S., et al. (2005). Response to splenectomy is durable after a certain point in time in adult ITP patients [Abstract 3976]. <i>Blood, 106<\/i>(Pt. 2), 73b-74b."},{"key":"E00050","unstructured":"Kahn, M.J., & McCrae, K.R. (2004). Splenectomy in immune thrombocytopenic purpura: Recent controversies and long-term outcomes. <i>Current Hematology Reports, 3<\/i>, 317-323."},{"key":"E00051","doi-asserted-by":"crossref","unstructured":"Kay, N.E., Geyer, S.M., Lin, T., Call, T.G., Jelinek, D.F., Bone, N.D., et al. (2004). Combination chemotherapy with pentostatin, cyclophosphamide and rituximab induces high rates of remissions including complete responses and achievement of minimal residual disease in previously untreated B-chronic lymphocytic leukemia [Abstract 339]. <i>Blood, 104<\/i>, 100a.","DOI":"10.1182\/blood.V104.11.339.339"},{"key":"E00052","doi-asserted-by":"crossref","unstructured":"Keating, M.J., Flinn, I., Jain, V., Binet, J.L., Hillmen, P., Byrd, J., et al. (2002). Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. <i>Blood, 99<\/i>, 3554-3561.","DOI":"10.1182\/blood.V99.10.3554"},{"key":"E00053","doi-asserted-by":"crossref","unstructured":"Keating, M.J., O'Brien, S., Albitar, M., Lerner, S., Plunkett, W., Giles, F., et al. (2005). Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. <i>Journal of Clinical Oncology, 23<\/i>, 4079-4088.","DOI":"10.1200\/JCO.2005.12.051"},{"key":"E00054","doi-asserted-by":"crossref","unstructured":"Koene, H.R. (2006). Critical issues of current and future developments in the treatment of immune thrombocytopenic purpura. <i>Pediatric Blood and Cancer, 47<\/i>(5, Suppl.), 703-705.","DOI":"10.1002\/pbc.20975"},{"key":"E00055","doi-asserted-by":"crossref","unstructured":"Kojouri, K., Vesely, S.K., Terrell, D.R., & George, J.N. (2004). Splenectomy for adult patients with idiopathic thrombocytopenic purpura: A systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. <i>Blood, 104<\/i>, 2623-2634.","DOI":"10.1182\/blood-2004-03-1168"},{"key":"E00056","doi-asserted-by":"crossref","unstructured":"Kuter, D., Bussel, J., George, J., Aledort, L., Lichtin, A., Lyons, R., et al. (2006). Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 48-week update [Abstract 476]. <i>Blood, 108<\/i>(Pt. 1), 144a.","DOI":"10.1182\/blood.V108.11.476.476"},{"key":"E00057","doi-asserted-by":"crossref","unstructured":"Kuwana, M., Okazaki, Y., Satoh, T., Asahi, A., Kajihara, M., & Ikeda, Y. (2005). Initial laboratory findings useful for predicting the diagnosis of idiopathic thrombocytopenic purpura. <i>American Journal of Medicine, 118<\/i>, 1026-1033.","DOI":"10.1016\/j.amjmed.2004.12.027"},{"key":"E00058","doi-asserted-by":"crossref","unstructured":"Lamanna, N., Kalaycio, M., Maslak, P., Jurcic, J., Heaney, M., Brentjens, R., et al. (2006). Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. <i>Journal of Clinical Oncology, 24<\/i>, 1575-1581.","DOI":"10.1200\/JCO.2005.04.3836"},{"key":"E00059","doi-asserted-by":"crossref","unstructured":"Lin, T.S., Heerema, N.A., Fischer, B., Blum, K.A., Moran, M.E., McEldowney, M.B., et al. (2006). Flavopiridol is active in genetically high-risk, relapsed chronic lymphocytic leukemia (CLL): Analysis of 56 patients by cytogenetic abnormality [Abstract 302]. <i>Blood, 108<\/i>(Pt. 1), 93a.","DOI":"10.1182\/blood.V108.11.302.302"},{"key":"E00060","doi-asserted-by":"crossref","unstructured":"Lin, T.S., Lucas, M.S., & Byrd, J.C. (2003). Rituximab in B-cell chronic lymphocytic leukemia. <i>Seminars in Oncology, 30<\/i>, 483-492.","DOI":"10.1016\/S0093-7754(03)00239-2"},{"key":"E00061","doi-asserted-by":"crossref","unstructured":"Lin, T.S., Moran, M., Lucas, M., Waymer, S., Jefferson, S., Fischer, D.B., et al. (2004). Antibody therapy for chronic lymphocytic leukemia: A promising new modality. <i>Hematology\/Oncology Clinics of North America, 18<\/i>, 895-913.","DOI":"10.1016\/j.hoc.2004.04.008"},{"key":"E00062","doi-asserted-by":"crossref","unstructured":"Lundin, J., Kimby, E., Bjorkholm, M., Broliden, P.A., Celsin, F., Hjalmar, V., et al. (2002). Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). <i>Blood, 100<\/i>, 768-773.","DOI":"10.1182\/blood-2002-01-0159"},{"key":"E00063","doi-asserted-by":"crossref","unstructured":"Mauro, F.R., Giammartini, E., De Propris, M.S., Gentile, G., Nanni, M., Ghia, E., et al. (2006). Fludarabine, Ara-C, novantrone and dexamethasone plus Campath-1H for the treatment of patients with chronic lymphocytic leukemia (CLL) and adverse clinical and biological prognostic features [Abstract 2830]. <i>Blood, 108<\/i>(Pt. 1), 801a.","DOI":"10.1182\/blood.V108.11.2830.2830"},{"key":"E00064","doi-asserted-by":"crossref","unstructured":"McMillan, R., & Durette, C. (2004). Long-term outcomes in adults with chronic ITP after splenectomy failure. <i>Blood, 104<\/i>, 956-960.","DOI":"10.1182\/blood-2003-11-3908"},{"key":"E00065","unstructured":"Mena, R.R., Robles, R., Auerbach, M., Moezi, M.M., & Headley, D. (2006). A multi-center, open-label study to evaluate the safety and efficacy of pentostatin, Cytoxan, and Rituxan (PCR) in the treatment of previously untreated or treated, stage II, III, or IV CLL [Abstract 4978]. <i>Blood, 108<\/i>(Pt. 2), 333b."},{"key":"E00066","doi-asserted-by":"crossref","unstructured":"Montserrat, E. (2004). Role of auto- and allotransplantation in B-cell chronic lymphocytic leukemia. <i>Hematology\/Oncology Clinics of North America, 18<\/i>, 915-926.","DOI":"10.1016\/j.hoc.2004.04.005"},{"key":"E00067","unstructured":"National Comprehensive Cancer Network. (2006). <i>NCCN clinical practice guidelines in oncology\u2122. Non-Hodgkin's lymphoma.<\/i> V. 1.2006. Jenkintown, PA: Author."},{"key":"E00068","doi-asserted-by":"crossref","unstructured":"Nichol, J.L. (2006). AMG 531: An investigational thrombopoiesis-stimulating peptibody. <i>Pediatric Blood and Cancer, 47<\/i>(5, Suppl.), 723-725.","DOI":"10.1002\/pbc.20972"},{"key":"E00069","doi-asserted-by":"crossref","unstructured":"O'Brien, S.M., Kantarjian, H., Thomas, D.A., Giles, F.J., Freireich, E.J., Cortes, J., et al. (2001). Rituximab dose-escalation trial in chronic lymphocytic leukemia. <i>Journal of Clinical Oncology, 19<\/i>, 2165-2170.","DOI":"10.1200\/JCO.2001.19.8.2165"},{"key":"E00070","doi-asserted-by":"crossref","unstructured":"O'Brien, S.M., Kipps, T.J., Faderl, S., Crump, M., Keating, M.J., Anderson, B., et al. (2005). A phase I trial of the small molecule Pan-Bcl-2 family inhibitor GX15-070 administered intravenously (IV) every 3 weeks to patients with previously treated chronic lymphocytic leukemia (CLL) [Abstract 466]. <i>Blood, 106<\/i>(Pt. 1), 135a.","DOI":"10.1182\/blood.V106.11.446.446"},{"key":"E00071","doi-asserted-by":"crossref","unstructured":"Penalver, F.J., Jiminez-Yuste, V., Almagro, M., Alvarez-Larran, A., Rodriguez, L., Casado, M., et al. (2006). Rituximab in the management of chronic immune thrombocytopenic purpura: An effective and safe therapeutic alternative in refractory patients. <i>Annals of Hematology, 85<\/i>, 400-406.","DOI":"10.1007\/s00277-006-0123-3"},{"key":"E00072","unstructured":"Psaila, B., Villarica, G., & Bussel, J.B. (2006). Insights into therapeutic mechanisms: Measuring immature platelet fraction (IPF) describes response to treatment in immune thrombocytopenic purpura (ITP) [Abstract 1070]. <i>Blood, 108<\/i>(Pt. 1), 319a."},{"key":"E00073","doi-asserted-by":"crossref","unstructured":"Rai, K.R., Peterson, B.L., Appelbaum, F.R., Kolitz, J., Elias, L., Shepherd, L., et al. (2000). Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. <i>New England Journal of Medicine, 343<\/i>, 1750-1757.","DOI":"10.1056\/NEJM200012143432402"},{"key":"E00074","doi-asserted-by":"crossref","unstructured":"Rai, K.R., Sawitsky, A., Cronkite, E.P., Chanana, A.D., Levy, R.N., & Pasternack, B.S. (1975). Clinical staging of chronic lymphocytic leukemia. <i>Blood, 46<\/i>, 219-234.","DOI":"10.1182\/blood.V46.2.219.219"},{"key":"E00075","doi-asserted-by":"crossref","unstructured":"Rai, K.R., Wasil, T., Iqbal, U., Driscoll, N., Patel, D., Janson, D., et al. (2004). Clinical staging and prognostic markers in chronic lymphocytic leukemia. <i>Hematology\/Oncology Clinics of North America, 18<\/i>, 795-805.","DOI":"10.1016\/j.hoc.2004.04.001"},{"key":"E00076","doi-asserted-by":"crossref","unstructured":"Ramadan, K.M., & El-Agnaf, M. (2005). Efficacy and response to intravenous anti-D immunoglobulin in chronic idiopathic thrombocytopenic purpura. <i>Clinical and Laboratory Haematology, 27<\/i>, 267-269.","DOI":"10.1111\/j.1365-2257.2005.00702.x"},{"key":"E00077","unstructured":"Ramanarayanan, J., Brodzik, F., Czuczman, M.S., & Hernandez-Ilizaliturri, F.J. (2006). Efficacy and safety of rituximab in the treatment of refractory\/relapsed idiopathic thrombocytopenic purpura (ITP): Results of a meta-analysis of 299 patients [Abstract 1076]. <i>Blood, 108<\/i>(Pt. 2), 321a."},{"key":"E00078","doi-asserted-by":"crossref","unstructured":"Rassenti, L.Z., Huynh, L., Toy, T.L., Chen, L., Keating, M.J., Gribben, J.G., et al. (2004). ZAP-70 compared with immunoglobulin heavychain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. <i>New England Journal of Medicine, 351<\/i>, 893-901.","DOI":"10.1056\/NEJMoa040857"},{"key":"E00079","unstructured":"Sandler, S.G., Schexneider, K., & Bhanji, R. (2006). Immune thrombocytopenic purpura. Retrieved January 10, 2007, from <a target=\"_blank\" href='http:\/\/www.emedicine.com\/med\/topic1151.htm'>http:\/\/www.emedicine.com\/med\/topic1151.htm<\/a>"},{"key":"E00080","doi-asserted-by":"crossref","unstructured":"Sayala, H.A., Moreton, P., Jones, R.A., Rawstron, A.C., O'Connor, S.J., Evans, P., et al. (2006). Final report of the UKCLL02 trial: A phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL Trials Sub-Group) [Abstract 34]. <i>Blood, 108<\/i>(Pt. 1), 14a-15a.","DOI":"10.1182\/blood.V108.11.34.34"},{"key":"E00081","doi-asserted-by":"crossref","unstructured":"Scully, M., Starke, R., Mackie, I., & Machin, S.J. (2006). Acute idiopathic thrombotic thrombocytopenic purpura: Predicting relapse and response to treatment [Abstract 1059]. <i>Blood, 108<\/i>(Pt. 1), 315a.","DOI":"10.1182\/blood.V108.11.1059.1059"},{"key":"E00082","doi-asserted-by":"crossref","unstructured":"Shanafelt, T., Byrd, J.C., Geyer, S.M., Bowen, D., LaPlant, B., Zent, C.S., et al. (2006). The pentostatin, cyclophosphamide, and rituximab regimen (PCR) is highly active and well tolerated regardless of patient age, creatinine clearance, and performance status: Analysis of a multi-center phase II trial [Abstract 36]. <i>Blood, 108<\/i>(Pt. 1), 15a.","DOI":"10.1182\/blood.V108.11.36.36"},{"key":"E00083","doi-asserted-by":"crossref","unstructured":"Stasi, R., Amadori, S., Osborn, J., Newland, A.C., & Provan, D. (2006). Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia. <i>Public Library of Science Medicine, 3<\/i>(3), e24.","DOI":"10.1371\/journal.pmed.0030024"},{"key":"E00084","doi-asserted-by":"crossref","unstructured":"Stasi, R., Pagano, A., Stipa, E., & Amadori, S. (2001). Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. <i>Blood, 98<\/i>, 952-957.","DOI":"10.1182\/blood.V98.4.952"},{"key":"E00085","doi-asserted-by":"crossref","unstructured":"Stasi, R., & Provan, D. (2004). Management of immune thrombocytopenic purpura in adults. <i>Mayo Clinic Proceedings, 79<\/i>, 504-522.","DOI":"10.4065\/79.4.504"},{"key":"E00086","doi-asserted-by":"crossref","unstructured":"Stilgenbauer, S., & Dohner, H. (2002). Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. <i>New England Journal of Medicine, 347<\/i>, 452-453.","DOI":"10.1056\/NEJM200208083470619"},{"key":"E00087","doi-asserted-by":"crossref","unstructured":"Stilgenbauer, S., Krober, A., Busch, R., Eichhorst, B., Kienle, D., Winkler, D., et al. (2005). 17p deletion predicts for inferior overall survival after fludarabine-based first line therapy in chronic lymphocytic leukemia: First analysis of genetics in the CLL4 trial of the GCLLSG [Abstract 715]. <i>Blood, 106<\/i>(Pt. 1), 212a.","DOI":"10.1182\/blood.V106.11.715.715"},{"key":"E00088","doi-asserted-by":"crossref","unstructured":"Strauchen, J.A. (2004). Immunophenotypic and molecular studies in the diagnosis and classification of malignant lymphoma. <i>Cancer Investigation, 22<\/i>, 138-148.","DOI":"10.1081\/CNV-120027589"},{"key":"E00089","doi-asserted-by":"crossref","unstructured":"Suvajdzic, N., Stankovic, B., Artiko, V., Cvejic, T., Bulat, V., Bakrac, M., et al. (2006). Helicobacter pylori eradication can induce platelet recovery in chronic idiopathic thrombocytopenic purpura. <i>Platelets, 17<\/i>, 227-230.","DOI":"10.1080\/09537100500462487"},{"key":"E00090","unstructured":"Tong, X., Georgakis, G.V., Long, L., O'Brien, S., Younes, A., & Luqman, M. (2004). In vitro activity of a novel fully human anti-CD40 antibody CHIR-12.12 in chronic lymphocytic leukemia: Blockade of CD40 activation and induction of ADCC [Abstract 2504]. <i>Blood, 104<\/i>, 686a."},{"key":"E00091","doi-asserted-by":"crossref","unstructured":"Trivedi, D.H., & Bussel, J.B. (2003). Immunohematologic disorders. <i>Journal of Allergy and Clinical Immunology, 111<\/i>(2, Suppl.), S669-S676.","DOI":"10.1067\/mai.2003.157"},{"key":"E00092","unstructured":"Vianelli, N., Galli, M., de Vivo, A., Intermesoli, T., Giannini, B., Mazzucconi, M.G., et al. (2005). Efficacy and safety of splenectomy in immune thrombocytopenic purpura: Long-term results of 402 cases. <i>Haematologica, 90<\/i>, 72-77."},{"key":"E00093","doi-asserted-by":"crossref","unstructured":"Wierda, W.G. (2006). Current and investigational therapies for patients with CLL. <i>Hematology, 2006<\/i>, 285-294.","DOI":"10.1182\/asheducation-2006.1.285"},{"key":"E00094","doi-asserted-by":"crossref","unstructured":"Wierda, W.G., O'Brien, S., Faderl, S., Ferrajoli, A., Ravandi-Kashani, R., Cortes, J., et al. (2006). Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL [Abstract 31]. <i>Blood, 108<\/i>(Pt. 1), 14a.","DOI":"10.1182\/blood.V108.11.31.31"},{"key":"E00095","doi-asserted-by":"crossref","unstructured":"Wierda, W.G., O'Brien, S., Ferrajoli, A., Faderl, S., Koller, C., Giles, F., et al. (2005). Salvage therapy with combined cyclophosphamide (C), fludarabine (F), alemtuzumab (A), and rituximab (R) (CFAR) for heavily pre-treated patients with CLL [Abstract 719]. <i>Blood, 106<\/i>(Pt. 1), 213a.","DOI":"10.1182\/blood.V106.11.719.719"},{"key":"E00096","doi-asserted-by":"crossref","unstructured":"Wierda, W.G., O'Brien, S., Wen, S., Faderl, S., Garcia-Manero, G., Thomas, D., et al. (2005). Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. <i>Journal of Clinical Oncology, 23<\/i>, 4070-4078.","DOI":"10.1200\/JCO.2005.12.516"},{"key":"E00097","doi-asserted-by":"crossref","unstructured":"Wiestner, A., Rosenwald, A., Barry, T.S., Wright, G., Davis, R.E., Henrickson, S.E., et al. (2003). ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. <i>Blood, 101<\/i>, 4944-4951.","DOI":"10.1182\/blood-2002-10-3306"},{"key":"E00098","doi-asserted-by":"crossref","unstructured":"Zhang, W.G., Ji, L., Cao, X.M., Chen, Y.X., He, A.L., Liu, J., et al. (2005). Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenia purpura. <i>Acta Pharmacologica Sinica, 26<\/i>, 598-602.","DOI":"10.1111\/j.1745-7254.2005.00088.x"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/24G346535455055N.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:51:02Z","timestamp":1763754662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/11\/1\/supplement-february-2007-b-cell-disorders\/emerging-therapeutic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,1]]},"references-count":98,"journal-issue":{"issue":"0","published-print":{"date-parts":[[2007,2,1]]}},"alternative-id":["24G346535455055N"],"URL":"https:\/\/doi.org\/10.1188\/07.cjon.s1.23-36","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2007,2,1]]}}}